The 'biggest GLP-1 mistake' claim: what the evidence actually says

What did @wellness_momma_christina actually say?

Christina, a self-identified physician assistant and cardiology PA, argues that the "single biggest mistake" people make on GLP-1 medications is chasing the highest dose. Her core claim: if you lose all hunger cues, your dose is too high. She frames this around a "low and slow" titration philosophy, warning that eating too little can trigger a weight-loss plateau and cause fatigue, weakness, and lightheadedness. She also describes GLP-1 as "a naturally occurring hormone secreted after you eat" that signals fullness, and ties obesity-related hunger dysregulation to leptin resistance. Along the way, she promotes access to GLP-1s through resources on her profile, outside of traditional insurance pathways.

Does the science back this up?

Partially, yes. The titration argument has real support, and the leptin resistance framing is legitimate. But the claim that total hunger suppression automatically signals an incorrect dose is an oversimplification that the clinical literature does not cleanly endorse.

GLP-1 receptor agonists do reduce appetite through central and peripheral mechanisms. Semaglutide, for instance, acts on hypothalamic neurons and slows gastric emptying, as documented by Drucker (2018, Cell Metabolism). The "low and slow" titration approach is genuinely supported by prescribing guidelines. The STEP trials for semaglutide used structured dose escalation specifically to reduce gastrointestinal side effects, not because lower doses are always equally effective long-term (Wilding et al., 2021, New England Journal of Medicine).

On leptin resistance: she is correct that obesity is associated with leptin resistance, which disrupts normal satiety signaling. This is well-established (Myers et al., 2010, Cell Metabolism). Where she oversimplifies is in treating complete appetite suppression as a red flag in isolation. Some patients experience profound appetite reduction at therapeutic doses without adverse outcomes.

What did they get wrong (or right)?

She gets the broad strokes right on titration. Rushing to maximum doses increases side effect burden without necessarily improving outcomes for every patient. That is a fair clinical point.

But her claim that "if you don't feel hunger at all, you're probably at too high of a dose" is not supported as a standalone diagnostic rule. Hunger suppression is actually a primary therapeutic mechanism, not a warning sign by itself. The clinical signal for dose adjustment is adverse effects, inadequate response, or safety concerns, not appetite suppression alone. She conflates a symptom of the drug working with evidence of overmedication.

Her description of GLP-1 as a hormone that "tells your body, hey, I'm full, you can stop eating now" is a reasonable lay explanation, though GLP-1's actions are more complex than a simple stop-eating signal. It also affects insulin secretion, glucagon suppression, and gastric motility (Nauck et al., 2021, Physiological Reviews).

The plateau claim, that eating too little causes a weight-loss stall, is biologically plausible via adaptive thermogenesis, but she presents it as more established than the evidence warrants. It is a reasonable concern, not a clinical certainty.

What should you actually know?

Dose decisions on GLP-1 medications belong with a licensed prescriber, full stop. A TikTok video is not a titration plan, and neither is your own hunger level on any given day.

The "low and slow" principle is real clinical practice. All approved GLP-1 agents, including semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), have structured titration schedules precisely because escalating too quickly increases nausea, vomiting, and dropout rates. The SURMOUNT-1 trial for tirzepatide showed meaningful weight loss across dose levels, with 5 mg showing significant efficacy before reaching 10 or 15 mg (Jastreboff et al., 2022, New England Journal of Medicine).

What she does not say clearly: the right dose is the one that achieves your clinical goals with tolerable side effects, as determined by your prescriber. Hunger suppression alone is not a reason to reduce your dose. If you are experiencing dangerous undernutrition, that is a medical issue requiring clinical evaluation, not a self-managed dose reduction based on a social media checklist.

Also worth noting: Christina promotes off-insurance access to GLP-1s through her profile. That pathway often involves compounded semaglutide or tirzepatide. Compounded versions are not FDA-approved and are not equivalent to brand-name drugs. Anyone using that route should understand what they are getting.